The whole pipeline of drugs is going to look very complicated if the numbers for Afrezza come back in line with expectations. Insulin is the "go-to" drug, but is deferred currently to the end of the progression of the disease due to all of the issues related to safety, convenience, stigma, and phobia. Let loose Afrezza and see what that slide deck looks like 12 months from now. IMO, they'd have no reason to keep chasing windmills with all of these convoluted drug prospects.